PAION AG Logo

PAION AG

ISIN

DE000A0B65S3

Ticker

PA8

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Germany

Year Founded

2000

About PAION AG

Company Description

PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.

In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Headcount

51

Served Area

Worldwide

Headquarters

Martinstraße 10-12
52062, Aachen
Germany

Filings & Publications

  • Consolidated Report 2021 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2022 - Q1 English πŸ‡¬πŸ‡§

Insider Trades

Date Trading entity / Person Association Trade type Volume
27.12.2022 Siebert, Gregor Board Buy EUR 24,110.26
22.12.2022 Dieckow, StB Simone Close relation Buy EUR 500,000.00
22.12.2022 Fuchs, Anna-Louisa Close relation Other EUR 0.00
21.12.2022 Zeitfracht GmbH & Co. KGaA Close relation Buy EUR 3,607,500.00

Capital Markets Information

ISIN

DE000A0B65S3

LEI

529900CGHB9UWY40BU45

Sub-Industry

Pharmaceuticals

Designated Sponsor

Oddo BHF Corporates & Markets AG

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.